A sign with the company logo is located on March 17, 2024 outside the headquarters Eli Lilly in Indianapolis, Indiana.
Scott Olson | Getty pictures
A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.
The competition on the Blockbuster -Weight Loss -Drug Market Market increases because the drug manufacturers share new data on new and existing treatments.
The annual conference of the American Diabetes Association in Chicago showed results for injections, pills and other therapies last weekend. Companies that are large and small companies compete for a piece of the weight loss drug space – and for good reason.
Some analysts estimate that the market could be worth more than 150 billion US dollars a year by the end of the decade. While I did not personally take part in the conference this year, I have summarized some highlights:
Eli Lilly steal the show – After the company's experimental pill, OFLIPRRON, Wall Street made easier relief and helped the patient to lose weight in a clinical study in the late stage.
The highest dose helped patients with type 2 diabetes during the 40-week study by 7.6% of their body weight, without signs of liver damage in daily treatment. Eli Lilly, who published the first data from the study in April, will present the results of a separate study on overweight or overweight patients without diabetes later this year. The company plans to start the pill next year.
The drug maker also teased the future of his portfolio and presented treatments that “could further expand Lilly's dominance in the room,” said Evan Seizerman, analyst of BMO Capital Markets, on Sunday in a note.
Another experimental Eli-Lilly drug, Bimagrumab, helped maintain lean muscle mass and wore a stronger fat loss in patients who took Novo Nordisk's popular obesity treatment in a study with medium-sized study.
Therapy seems to offer a potential solution for a problem that has arisen with existing weight loss injections. Some doctors are concerned that patients may lose too much meager muscle mass while they make their shots, especially older adults who can be more frail.
Eli Lilly is now conducting additional studies of the drug in combination with its own weight loss injection, Zepbound, Ken Custer, President of the Lilly Cardiometabolic Health, to CNBC.
“We think we can get even better [results] On Tirzatide, “said Custer and referred to the active ingredient in Zepbound.
Another experimental therapy from Eli Lilly also helped the patient to lose only a few side effects in a small study, which impressed analysts. The drug, referred to as elalintide, is part of a class of medication that mimic the hormoneamylin that slows down the digestion and feel fuller.
Novo Nordisk catch up – While Eli Lilly tries to maintain or expand his lead on the weight loss drug market, the chief rival Novo Nordisk published the full results from studies in the late stage to his experimental weekly injection, Cagrisema.
Investors hammered the company's share in December after the results of preliminary studies showed that Cagrisema had missed its aim of 25% average weight loss, with less than half of the patients achieved this goal.
Flags with the logos of the Danish drug maker Novo Nordisk, manufacturer of the blockbuster diabetes and weight loss treatments Ozempic and Wegovy are pictures, while the company introduces the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.
Mads Claus Rasmussen | AFP | Getty pictures
However, the complete results show that patients have lost a significant weight, even if they chose a lower dose of the treatment. The studies made it possible for patients to stop in lower doses if they wanted to treat side effects or if they already lost enough weight.
The complete data at the conference also highlighted a “relatively clean security profile” for Cagrisema, said Seigerman in a separate note on Monday. The drug had similar side effects to Wegven, although it provided more weight loss.
Cagrisema is a combination of cagilintide – imylin imitating – and Semaglutid, the active ingredient in Wegovy.
Novo Nordisk also published data from two early attempts on another experimental medicine called Amycretin.
The drug helped the patient to lose up to 24.3% of their weight after 36 weeks after 36 weeks, and also showed signs of improving blood sugar levels with side effects in general in harmony with other obese medications.
Treatment uses the same intestinal hormone as they underline the appetite and regulate blood sugar, but also combines with amylin.
The companies are planning to bring both injectable and oral versions of amycletin to attempts in the late stage for weight management, Novo Nordisk said in a press release.
Amgen Outline the next steps for the injection of obesity – While Amgen tries to hit waves in the race with two shops, it has to improve the results from attempts in the late stage to its experimental monthly weight loss injection, said Seigerman in a separate note on Monday.
Amgen has set its plan for the weight loss market, which is based on the results for two attempts at the conference.
The company said that his medication, maritide, had led to a significant weight loss, but high rates of side effects and discontinuations in a medium -level study. Amgen published the first data from this study in November.
The rates of patients who dropped the medicine due to side effects were high and was between 10% and 29% within various groups that took it. The vomiting rates were between 43% and 92%. Groups of patients who gradually increased the dosage had lower interruption rates and vomiting than those who did not do this.
A smaller phase -1 study, however, showed that the starting of patients with lower maritide doses and the use of a gradual dose scalation on how well they tolerated the drug. The two groups with the lowest initial cans had vomiting rates of around 23% and 24%, and there were no interruptions due to side effects.
“Lower starting cans and other steps help patients,” Jay Bradner, Executive Vice President for Research and Development at AMgen, told CNBC.
The Amgen logo will be exhibited on May 17, 2023 outside the Ambem headquarters in Thousand Oaks, California.
Mario Tama | Getty pictures
He added that the side effects of Maritide were “short-lived” and that the data informed the design of the 72-week phase-thirds phase trial studies from Amgen as a medicine. In these studies, the company uses lower starting cans over a period of eight weeks and three steps of the dosiscalation over a period of eight weeks. In week eight, the patients become one of three different target doses of Maritide.
“What we achieve through a dose escalation is to tolerate the next step of the doses to the brain,” said Bradner and found that it is a strategy used with Wegovy and Zepbound.
But Maritide may have an advantage over these competing treatments, as it will take fewer steps and the cans will increase over a shorter period of time, he said.
In a note on Monday, Jefferie's analyst said that the three data will go into “better than expectations”. They said that the most important snack is that Amgen's lower and slower dosage plan significantly improve the side effects and the lower discontinuations and the effectiveness in the studies when the patients remain in the medicine and experience their full effects.
At the end of the year, according to Bradner, Amgen will also have data on patients who have taken Maritide every quarter.
Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.
Latest in the healthcare system Tech: Abridge announces a funding round of $ 300 million, while AI documentation tools withdraw
The investments simply flow in again and again.
Abridge announced on Tuesday that it completed a financing round of 300 million US dollars under the direction of Andreessen Horowitz with the participation of Khosla Ventures. The round comes only a few months after the startup has collected another 250 million US dollar at Fresh Capital at the beginning of this year.
Abridge was founded in 2018 and used artificial intelligence to design clinical notes in real time because the doctors record their visits with patients mutually. The startup is part of a market that exploded as managers in the healthcare system to search for solutions in order to reduce employees of employees and to discourage the administrative workload.
According to the PitchBook, Abridge has now collected almost 818 million US dollars and has collected a place in the list of Disruptor 50 from CNBC this year with more than 150 health systems in the USA.
“Ultimately, it is a privilege to continue to have the effects that we still want for clinicians, patients and other members of the health ecosystem,” said Julia Chou, Chief Operating Officer from Abridge, in an interview with CNBC.
Chou said that the fresh capital of abridge would help the company to go beyond traditional clinical notes. The startup is working on embedding relevant intake cycle information into its product, which would help to ensure that the documentation is relieved of compliant and downstream workflows.
Moving is not the only AI documentary startup that thinks about the billing of health care.
Another AI -Script startup, ambience Healthcare, has also examined applications for sales cycle management. In May, the company announced a new medical coding model that can be used to listen to patient encounters and identify ICD-10 codes, which are internationally standardized classifications for different diseases and conditions.
According to the PitchBook, Ambience has collected more than 100 million US dollars from investors such as small Perkins, Andreessen Horowitz and the Openai Startup Fund. According to a report from the information, the company is looking for a new capital with an evaluation of over 1 billion US dollars.
The printing of AI Scripting Companies in the billing could help you to market your products as real sales drivers and not just time -saving tools to the health systems from cash.
Made down says it is just starting.
“AI comes to the doctor's office,” said Chou. “The striving is that it really feels your visits.”
Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.
